Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9% – Should You Sell?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded down 6.9% on Thursday . The stock traded as low as $6.62 and last traded at $6.64. 6,100,949 shares were traded during mid-day trading, a decline of 0% from the average session volume of 6,122,622 shares. The stock had previously closed at $7.13.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, November 20th. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group dropped their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating for the company in a research report on Tuesday, September 3rd. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Stock Down 3.6 %

The company has a market cap of $1.97 billion, a price-to-earnings ratio of -4.34 and a beta of 0.85. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm’s fifty day moving average price is $6.60 and its 200-day moving average price is $7.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals’s quarterly revenue was up 147.6% on a year-over-year basis. During the same period last year, the firm earned ($0.43) EPS. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Christopher Gibson sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total value of $123,200.00. Following the completion of the transaction, the chief executive officer now owns 762,656 shares in the company, valued at $4,697,960.96. This trade represents a 2.56 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $6.84, for a total value of $78,297.48. Following the completion of the transaction, the director now owns 7,109,875 shares of the company’s stock, valued at $48,631,545. The trade was a 0.16 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 134,235 shares of company stock valued at $895,538. Company insiders own 15.75% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at about $5,769,000. Pier 88 Investment Partners LLC lifted its stake in Recursion Pharmaceuticals by 442.1% in the 3rd quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company’s stock valued at $882,000 after purchasing an additional 109,210 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its stake in Recursion Pharmaceuticals by 6,439.6% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company’s stock valued at $1,274,000 after purchasing an additional 167,302 shares during the last quarter. Scientech Research LLC acquired a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at about $1,052,000. Finally, Ghisallo Capital Management LLC acquired a new stake in Recursion Pharmaceuticals in the 2nd quarter valued at about $8,250,000. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.